Cyclopharm’s US Revenue More Than Doubles as Technegas Rollout Expands
CYC: $0.385 +4.05% · MC: $58M
Cyclopharm reported record quarterly US revenue, more than double the same period a year earlier and up nearly half from the previous quarter. US revenue for the first nine months exceeded the whole of the previous year, while the installed base of Technegas systems grew by more than four-fifths over six months. Group revenue rose by nearly a seventh over the nine months, and average monthly cash burn roughly halved from the second half of the previous year.

Comments